Newsfeeds Archive - Page 14 of 56

2 minute read

Up To $285M In Financing: COMPASS Pathways’ Private Placement Backed By ‘Select Group’ Of Investors

August 16, 10:47 AM

Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group of healthcare specialist investors.

CMPS

2 minute read

Filament Health Shares Q1 2023 Financials, Material Uncertainties Upon Securing Additional Financing

By Lara Goldstein

August 15, 6:21 PM

Natural psychedelic drug development company Filament Health (OTCQB: FLHLF) has released its unaudited consolidated, condensed financial results for Q1 2023 ended June 30. Numbers show:

FLHLF

2 minute read

Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs

By Lara Goldstein

August 15, 5:44 PM

Novel psychedelic-based drugs biotech Mydecine Innovations Group (OTC: MYCOF) shared its financial results for the six months ended June 30, 2023. Second quarter of FY2023 looks like this: Cash position of $29.987 (CA $40,458) as of June 30, 2023.

MYCOF

2 minute read

Cybin’s Q1 2023 Financials, Deuterated Psychedelics Moving ‘Steadily’ Through The Clinic

By Lara Goldstein

August 14, 6:07 PM

Canadian clinical-stage psychedelics company Cybin (NYSE: CYBN) shared its unaudited financial results for the first quarter ended June 30, 2023:

CYBN

3 minute read

Enveric’s Q2 2023 Financials Show Immediate Need For Budget-Slimming Toward A Clinical-Staged 2024

By Lara Goldstein

August 14, 2:58 PM

Next-gen psychedelics business Enveric Biosciences (NASDAQ: ENVB) reported its unaudited financial results for the second quarter of 2023 ended June 30. Results show:

ENVB

2 minute read

MindMed Inks $50M Credit Facility Deal With K2 HealthVentures For An Additional Operational Year

By Lara Goldstein

August 14, 2:45 PM

Clinical-stage psychedelics biotech MindMed (NASDAQ: MNMD) has secured a new financing source by entering into a $50 million senior secured credit facility with K2 HealthVentures, an alternative investment firm focused on providing “flexible, long-term financing solut

MNMD

4 minute read

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More

By Lara Goldstein

August 14, 9:46 AM

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

AGNPF

3 minute read

Atai’s Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline’s Psilocybin, DMT, Ketamine & MDMA

By Lara Goldstein

August 10, 5:06 PM

Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show:

ATAI

2 minute read

Atai’s Clinical Results Of R-Ketamine For Depression: Road To Subcutaneous At-Home Administration

By Lara Goldstein

August 9, 4:51 PM

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) shared results from majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of its proprietary R-ketamine compound PCN-101.

ATAI

2 minute read

Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma’ Nasal Formulation For Ketamine-Based Treatment

By Lara Goldstein

August 8, 4:19 PM

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug SPC-15.

SILO